The Outlook for Pharmaceuticals in Latin America to 2012

Abstract

The eight Latin American markets covered by Espicom represent a market of 468 million people with a GDP of US$2.7 trillion in 2007. Each country report provides a comprehensive analysis of the pharmaceutical market, including five-year market forecasts. For each country you will receive 4 completely updated reports sent quarterly, plus comprehensive report sent annually

The pharmaceutical markets in Latin America are worth US$41 billion - and growing fast!

The eight Latin American markets covered by Espicom represent a market of 468 million people with a GDP of US$2.7 trillion in 2007. Fuelled by Mexico, Brazil, Argentina and Venezuela, they are expected to represent a market value of US$63 billion at retail prices by 2012.

The region aims to increase its global position, in an effort to counteract other emerging markets, particularly China and India. The Mercosur and Andean groups, however, have proved to be quite impractical to align its members in a common front.

Bilateral free trade agreements with the USA continue, Uruguay being the last wishing to follow Chile' s successful move; Peru and Colombia are on their way. Opportunities remain as Argentina is mirroring Brazil in order to increase its industrial capabilities whilst Mexico is keeping its pace.

Combined domestic production stood at US$17.9 billion in 2004, led by Mexico (US$8.0 billion) and Brazil (US$5.8 billion). Pharmaceutical imports increased to a combined US$7.8 billion whilst pharmaceutical exports rose to US$2.4 billion in 2005. Brazil had the highest negative balance of trade, valued at US$2.1 billion, followed by Mexico (US$1.4 billion).

These reports analyse the issues

That is why Espicom Business Intelligence has published these new management reports The Outlook for Pharmaceuticals in Latin America to 2012. Each report provides an individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually or as a discounted collection, and prices include 4 completely updated reports sent quarterly plus a comprehensive annual review.